Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies
about
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?Bispecific antibodies and their applicationsSite-specific functionalization of proteins and their applications to therapeutic antibodiesBispecific T-cell engagers for cancer immunotherapy.Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteImmunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and ProteinsCharacterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancerCatumaxomab: clinical development and future directionsAdvances in Antibody DesignModern Technologies for Creating Synthetic Antibodies for Clinical application.Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent ModelsImmunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.Solid-phase bioconjugation of heterobifunctional adaptors for versatile assembly of bispecific targeting ligands.Cancer therapy with bispecific antibodies: Clinical experience.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodiesSpecific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine.Symmetry breaking: bispecific antibodies, the beginnings, and 50 years onA novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cellsEfficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges.Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumorsInduction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification.Therapeutic antibodies: successes, limitations and hopes for the future.Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.The making of bispecific antibodiesA detergent-based procedure for the preparation of IgG-like bispecific antibodies in high yield.Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
P2860
Q24644083-CCCF8320-A545-46B9-8C6A-D54BF826CBB0Q26774024-9CF535E1-61A5-4EAB-8A44-6B4BC1341AECQ26830699-0DEC8C6F-2C19-49A9-B581-E203B36FA727Q27693313-AC700879-0173-4966-8BF0-78700C0847ACQ28066935-DD9A7D4A-6192-450C-8774-FE62F30913C6Q28072319-E6737157-7209-4E6B-9686-74BED68010ACQ28235980-2C2817B0-CB32-4D9D-9672-16540037EF09Q28274519-3565072C-30EE-49A3-AF09-8447BA9C2508Q28817608-D88540FB-A7ED-4C60-BE09-1C52A8B49700Q30467308-F5898CC9-4A98-4B03-92C6-03C171BE45E8Q33588273-988098A9-D6D6-413E-A734-CE1FBF59899BQ33740334-2B8C6052-AA82-4DBE-9581-B3F149A17F16Q33781380-E4C67C24-CD07-4DA7-B0E4-8C8FD83FC5ABQ34074743-E850A961-2F37-41A4-9B34-3B1FDD8C0FD7Q34118856-FC500ABF-8D7A-44B8-810D-3FC667C0AC39Q34548319-EA335560-650D-46E9-88BB-160213820D37Q34550963-98F2B4CC-3552-4B9F-9EB6-E178CF6C2534Q34662933-890E19CC-AB49-4F94-B608-83FED8978D8FQ35090965-CF111CF9-4D3C-4444-8680-9FF10466DA9CQ35699518-32E770AF-72DE-43BC-A761-684434FBA5A2Q36050013-27B4D8E4-11CB-4CCD-9935-D7FD8F6F3190Q36363779-BA9269FE-4832-4E33-8B8A-DF22907923B8Q36621733-3D0BA232-E383-4098-B450-DC417247F72AQ36729822-B279ABD7-3DC3-478B-A16C-F96C5C396A26Q36746340-506EF661-DC07-4BDE-9924-F6F6DE01262CQ36821533-9E243F06-360D-4617-A5FC-70FF76E9C0CAQ37076922-4D300F66-76EB-47F0-80D8-1CF9230CF263Q37102182-E4F52F16-84FC-4C5B-BDF9-9DA2DA225D38Q37212191-5096984A-7D42-474B-8460-0C804EB45AB7Q37491236-84115C58-4220-46A2-B697-FEBAF65761ECQ37496596-99DCABE6-DAA8-4841-84B8-2FC116BF0686Q37593702-4429BB66-ABC7-4B2E-8D0C-9C0299FF72D4Q38038410-A937DD08-BF60-4DBA-AA0E-D449BD59273DQ41719908-F4C47415-D7E5-44CD-A0A2-851B3C78533EQ41864920-9AB7DCA3-B5EF-448D-B43C-D24DB3B2898EQ42323236-87BF3244-A41C-4352-BDBD-4CF6190A4E34Q42351565-6B4F4FAF-F98D-4934-B616-BB6DB5D3DD8DQ42392973-74842A8C-2A5F-4B44-A370-0FDED3DD9DDCQ43155636-CCC143F2-9ECB-4668-8EAB-D6D319FA690BQ47099672-03E494BD-EF0C-4CE3-A8C1-DA63EDCCC4E1
P2860
Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Preferential species-restricte ...... ation of bispecific antibodies
@ast
Preferential species-restricte ...... ation of bispecific antibodies
@en
Preferential species-restricte ...... ation of bispecific antibodies
@nl
type
label
Preferential species-restricte ...... ation of bispecific antibodies
@ast
Preferential species-restricte ...... ation of bispecific antibodies
@en
Preferential species-restricte ...... ation of bispecific antibodies
@nl
prefLabel
Preferential species-restricte ...... ation of bispecific antibodies
@ast
Preferential species-restricte ...... ation of bispecific antibodies
@en
Preferential species-restricte ...... ation of bispecific antibodies
@nl
P2093
P3181
P1476
Preferential species-restricte ...... ation of bispecific antibodies
@en
P2093
Lindhofer H
Thierfelder S
P304
P3181
P407
P577
1995-07-01T00:00:00Z